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Abstract 
Background We aimed to examine cardiovascular risk factors and health behaviors in patients with acute 
coronary syndromes (ACS) according to potential extension of eligibility criteria for protein convertase 
subtilisin/kexin-9 inhibitors (PCSK9i) to all patients with low-density lipoprotein cholesterol (LDL-c) equal 
or above 1.8 mmol/l. 
Methods In this prospective cross-sectional study, patients with ACS between 2009 and 2016 and with 
available LDL-c at one year were considered. We defined three mutually exclusive groups of patients 
according to eligibility for PCSK9i: “not eligible”, “currently eligible”, and “newly eligible”. We explored the 
control of cardiovascular risk factors and health behaviors. 
Results Out of 3,025 patients who had an ACS one year ago, 1,071 (35.4%) were not eligible for 
PCSK9i, 415 (13.7%) were currently eligible, and 1,539 (50.9%) were newly eligible. The proportion of 
patients with uncontrolled hypertension in the not eligible group was lower than in the group currently 
eligible (27.6% vs 33.6%, p=0.02), but similar to the group newly eligible (27.6% vs 28.2%, p=0.73). The 
proportion of smokers in the not eligible group was lower than in the group currently eligible (21.2% vs 
28.0%, p=0.02), but similar to the group newly eligible (21.2% vs 22.5%, p=0.51).  
Conclusions More than half of patients with ACS would be additionally eligible for PCSK9i if prescription 
is extended from current guidelines to all patients with LDL-c equal or above 1.8 mmol/l. Patients 
currently eligible for PCSK9i one year after an ACS had a worst control of cardiovascular risk factors than 
patients potentially newly eligible. 
 
Keywords Protein convertase subtilisin/kexin-9 inhibitors; low-density lipoprotein cholesterol; acute 
coronary syndromes; cardiovascular prevention; cardiovascular disease. 
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Introduction 
Proprotein convertase subtilisin/kexin 9 inhibitors (PCSK9i) are a new class of cholesterol lowering drugs 
that reduce cardiovascular events among patients with atherosclerotic cardiovascular disease and high 
low-density lipoprotein cholesterol (LDL-c) levels despite statins.(1-4) Because only one third of patients 
with acute coronary syndromes (ACS) can achieve a level of LDL-c below 1.8 mmol/l with statins, PCSK9i 
are a real opportunity to improve the management of lipids and cardiovascular risk among patients with 
ACS.(5) Both the latest European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) and 
the American Heart Association/American College of Cardiology (ACC/AHA) guidelines for the 
management of cholesterol recommend using lipid-lowering drugs in an incremental strategy to decrease 
LDL-c to a target level of <1.8 mmol/l among patients with cardiovascular disease.(6-11) However, with 
elevated annual costs per patient, PCSK9i reimbursement is limited by healthcare insurances in many 
countries. In Switzerland, current eligibility criteria for reimbursement are based on the latest ESC/EAS 
guidelines: patients with LDL-c >3.5 mmol/l in case of a first cardiovascular event, or alternatively >2.6 
mmol/l in case of a recurrent cardiovascular event within a 5-year period.(11)  
 
Recent randomized controlled trials showed cardiovascular benefits to further reduce the LDL-c with the 
addition of a PCSK9i on top of statins.(1, 2) Among patients with atherosclerotic cardiovascular disease, 
the addition of evolocumab reduced the LDL-c median value from 2.4 mmol/l to 0.8 mmol/l over 2.2 
years.(1) Among patients with an acute coronary syndrome, the addition of alirocumbab reduced the LDL-
c median value from 2.4 mmol/l to 1.7 mmol/l over 2.8 years.(2)  Thus, discussions are now ongoing to 
extend the current eligibility for PCSK9i prescription and reimbursement to all patients with atherosclerotic 
cardiovascular disease and a LDL-c equal or above 1.8 mmol/l. 
 
However, only few data exist about how to implement evidence from randomized controlled trials into 
clinical practice. Particularly, the means put in place to control cardiovascular risk factors other than LDL-
c and the health behaviors of patients with ACS can largely influence the risk or recurrence. This is 
important because PCSK9i may have a larger benefits among patients with higher global cardiovascular 
risk.(12) The latest 2018 ACC/AHA cholesterol clinical practice guidelines recommend using PCSK9i only 
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in patients with cardiovascular disease who have additional high-risk conditions.(6) To examine this issue, 
we aimed to compare the level of control of cardiovascular risk factors and motivation to change health 
behaviors among a representative sample of patients with ACS, taking into account potential new 
eligibility criteria for PCSK9i prescription. 
 
Patients and methods 
Study population 
We studied patients who were part of the Special Program University Medicine-Acute Coronary 
Syndromes (SPUM-ACS) study, an observational prospective Swiss cohort of consecutive patients 
hospitalized for ACS.(13) The aim of the SPUM-ACS study is to assess the quality of care after an ACS 
and identify new biomarkers for coronary heart disease prevention. For this analysis, we considered only 
the random sample of patients with measured LDL-c performed 12 months after the index ACS 
(Supplemental Figure 1). Inclusion criteria for the index ACS were age ≥18 years and diagnosis of ST-
elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), or unstable 
angina. Exclusion criteria were severe physical disability, inability to give consent due to dementia, or life 
expectancy of less than one year for non-cardiac reasons. Out of 6,359 ACS patients included from 2009 
to 2016 with available follow-up information, a random sample of 3,025 patients had available 
measurements of LDL-c levels at 12 months. 
 
Eligibility for prescription of PCSK9i 
One year after the index ACS, we defined three mutually exclusive groups of patients according to 
eligibility criteria for PCSK9i based on ESC/EAS guidelines (Supplemental Table 1).(11) The first category 
included “not eligible” patients and was defined as LDL-c <1.8 mmol/l one year after the index ACS. The 
second category was “currently eligible” patients when their LDL-c was >3.5 mmol/l, or >2.6 mmol/l for 
those who had several cardiovascular events. The third category was “newly eligible” patients when their 
LDL-c was between 1.8 and 2.6 mmol/l, or between 2.6 and 3.5 mmol/l for those with only one 
cardiovascular event. Furthermore, we performed sensitivity analyses to compare the “not eligible” group 
to all potential eligible patients with a LDL-c of 1.8 mmol/l or above, which correspond to the combination 
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of the “currently eligible” and “newly eligible” groups. The assessment of cardiovascular events other than 
the index ACS was determined with the self-reported history of previous cardiovascular disease that 
occurred any time before the index ACS, or alternatively the occurrence of an adjudicated myocardial 
infarction, stroke, peripheral artery disease, angina or unplanned revascularization over the year after the 
index ACS. Self-reported previous cardiovascular disease before the index ACS included coronary heart 
disease, ischemic cerebrovascular disease or peripheral artery disease. A similar methodology has been 
used and reported previously to assess eligibility for PCSK9i according to several guidelines in this 
cohort.(14)  
 
Outcomes assessed one year after the index ACS 
One year after the index ACS, clinical information, questionnaires and biologic parameters were 
measured or collected by trained study nurses and doctors during a face-to-face visit, and gathered using 
a standardized web-based case report forms available in all participating centers.(15). Smoking cessation 
was defined as having stop smoking over the year after the index ACS. Smokers with missing information 
regarding smoking status at one year were considered as current smokers. Patients with Body Mass 
Index (BMI) > 30 kg/m2 were defined as obese. Weight change in kilogrammes was calculated as weight 
at one-year follow-up minus weight at the index ACS. Weight drop was defined as the ratio of negative 
weight change over the weight at the index ACS and was dichotomized into less than 5%, and 5% and 
more. The International Physical Activity Questionnaire (IPAQ)(16) was analyzed to assess the level of 
physical activity at the time and one year after the index ACS. Volume of physical activity was reported in 
metabolic equivalent (MET) minutes per week. Patients with ≤ 600 MET minutes per week of physical 
activity were defined as sedentary. Patients with 0 or more than 2500 MET minutes per week of physical 
activity were excluded from the analysis to avoid misclassification. Change of physical activity over the 
year after the index ACS was dichotomized into increased activity, and stabilisation or decreased activity. 
Motivation scales with ten levels were used to measure motivation to change health behaviors regarding 
general health, diet, physical exercise, and smoking cessation one year after the index ACS. No 
motivation was defined as a score of 1, and best motivation as a score of 10. 
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Definitions of co-variables 
Diabetes one year after the index ACS was defined as the use of antidiabetic medication or a 
hemoglobinA1c of 6.5% or greater measured at the one-year visit, or as having diabetes at the time of the 
index ACS. High systolic blood pressure was defined has having a systolic blood pressure > 140 mmHg. 
Alcohol use was reported in units per week. Patients with more than 14 unit per week of alcohol were 
defined as at risk consumer. High-Intensity statin therapy was defined according to current lipid 
guidelines.(9) Levels for total cholesterol, high-density lipoprotein cholesterol (HDL-c) and triglycerides 
were measured locally using standardized dosage methods, and LDL-c was calculated using the 
Friedewald formula.  Familial hypercholesterolemia was defined according to Dutch Lipid Clinic Network 
score (possible, probable or definite). Anti-hypertensive therapy was defined as the use of angiotensin 
converting enzyme inhibitors, or angiotensin II receptor blockers, or beta-blockers, or calcium-channel 
blockers, or diuretics. We defined three categories for number of drugs administrated: between 0 and 5, 6 
and 8, and over 8 drugs. Drugs included use of Acetylsalicylic acid, Clopidogrel, Prasugrel, Ticagrelor, 
anticoagulants, statins, lipid-lowering therapy other than statins, angiotensin converting enzyme inhibitors, 
angiotensin II receptor blockers, beta-blockers, calcium-channel blockers, diuretics, nonsteroidal anti-
inflammatory drugs, Amiodarone, Digoxin, antidepressants, Dipyridamole, other antiarrhythmic drugs, 
immunosuppressive therapy, antiretroviral therapy, hormonotherapy. The Center for Epidemiological 
Studies-Depression (CES-D) self-assed questionnaire was used to screen for depression (score ≥ 16). 
The EQ-5D with 3 levels of severity for each of the 5 dimensions (EQ-5D-3L) questionnaire was used to 
measure health-related quality of life. Scores of the 5 dimensions were summed up and total score of 5 
was defined as best quality of life, and total score of 15 as worst quality of life. The EQ visual analogue 
scale (EQ VAS) with a score from 0 (worst imaginable health state) to 100 (best imaginable health state) 
was used to measure health-related quality of life that reflects the patient’s own judgement. 
 
Statistical analysis 
We categorized patients according to eligibility criteria for PCSK9i in three groups. We reported clinical 
characteristics, health care utilization, medication, and cardiovascular risk factors in each three groups. 
“Newly eligible” and “currently eligible” groups were each compared to the “not eligible” group using 
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Student's t-tests for continuous variables, and Chi-square tests for categorical variables. Continuous 
variables are reported as mean with standard deviation, whereas categorical variables as actual numbers 
with percentages. All analyses were conducted in STATA version 14.0® (STATA Corporation, College 
Station, TX, USA). The significance level was set at 0.05. 
 
Ethics statement 
The study was approved by Medical Ethics Committees of each center (Lausanne, Geneva, Bern and 
Zurich) and conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave 
written informed consent to participate. 
 
Results 
One year after their ACS, 3,025 patients were alive with available LCL-c values. Overall, 1,071 (35.4%) 
patients had well-controlled LDL-c and were not eligible for PCSK9i, 415 (13.7%) were currently eligible, 
and 1,539 (50.9%) were newly eligible for PCSK9i. Clinical characteristics of patients with respect to 
these three categories are reported in Table 1. The use of statins in the not eligible group was higher 
compared to the group currently eligible (99.1% vs 74.3%, p<0.001), and to the group newly eligible 
(99.1% vs 95.3%, p<0.001). The use of ezetimibe in the not eligible group was lower compared to the 
group currently eligible (7.3% vs 7.5%, p=0.9), and higher compared to the group newly eligible (7.3% vs 
6.2, p=0.29). The proportion of patients with only one cardiovascular event in the not eligible group was 
higher compared to the group currently eligible (73.8% vs 36.9%, p<0.001), and lower compared to the 
group newly eligible (73.8% vs 81.5%, p=<0.001). The proportion of patients with diabetes in the not 
eligible group was higher compared to the group currently eligible (23.4% vs 15.6%, p=0.001), and to the 
group newly eligible (23.4% vs 14.9%, p<0.001). Health-related quality of life in the not eligible group was 
better compared to the group currently eligible (6.2 vs 6.5, p=0.001), and similar to the group newly 
eligible (6.2 vs 6.2, p=0.77).  
 
Comparisons of health care and preventive drugs utilizations one year after the index ACS are reported in 
Table 2. The use of anti-hypertensive therapy in the not eligible group was higher compared to the group 
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currently eligible (95.5% vs 89.2%, p<0.001), and similar to the group newly eligible (95.5% vs 93.4%, 
p=0.02). Similarly, the proportion of patients who had attended a follow-up visit with a cardiologist in the 
not eligible group was higher compared to the group currently eligible (83.5% vs 75.1%, p=0.001), and 
similar compared to the group newly eligible (83.5% vs 84.1%, p =0.67).  
 
Control of cardiovascular risks factors one year after the index ACS is reported in Table 3. The proportion 
of patients with systolic blood pressure > 140 mmHg in the not eligible group was lower compared to the 
group currently eligible (27.6% vs 33.6%, p=0.025), and similar to the group newly eligible (27.6% vs 
28.2%, p=0.73). The proportion of current smokers in the not eligible group was lower compared to the 
group currently eligible (21.2% vs 28.0%, p=0.02), and similar to the group newly eligible (21.2% vs 
22.4%, p=0.52). The proportion of patients with diabetes and glycated hemoglobin ≥7.5% in the not 
eligible group was lower compared to the group eligible (25.9% vs 35.7%, p=0.2), and similar to the group 
newly eligible (25.9% vs 24.2%, p=0.72). When comparing all potential eligible participants to those not 
eligible because of a LDL-c < 1.8 mmol/l, there were no differences in the control of cardiovascular risks 
factors (Supplemental Table 2). 
 
Change in health behaviors over the year after the index ACS according to eligibility for PCSK9i is shown 
in Figure 1. Mean weight change for obese patients was a loss of 1.7 kg for those not eligible, a gain of 
0.3 kg for those currently eligible (p=0.01), and a loss of 1 kg for those newly eligible (p=0.29). However, 
there were no difference in change in physical activity among sedentary patients across the three groups. 
Motivation to change health behaviors assessed with motivation scales are shown in Supplemental 
Figure 2. In the three groups, the highest motivation to change concerned general health. There were no 
differences in motivation to change general health, diet or physical activity between the three groups. 
Motivation to stop smoking in the not eligible group was higher compared to the group currently eligible 
(p=0.0025), and similar to the group newly eligible (p=0.23). 
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Discussion 
In this multicenter observational study of patients post ACS, we found that half of them would be newly 
eligible for PCSK9i if current prescription criteria were extended to all ACS patients with a persistent LDL-
c equal or above 1.8 mmol/l. However, except for LDL-c levels, those patients who were potentially newly 
eligible for PCSK9i had a similar control of cardiovascular risk factors than patients with well-controlled 
LDL-c levels below 1.8 mmol/l. Moreover, patients who would be newly eligible for PCSK9i had a better 
health profile than those who were currently eligible; they were relatively younger and had a better control 
of cardiovascular risk factors and lifestyle habits, including higher smoking cessation rates, lower high 
blood pressure rates, higher physical activity rate, or higher optimal weight drop rates. Our data also 
suggest that those patients who would be newly eligible for PCSK9i had better adherence to preventive 
drugs than those who were currently eligible, which made their profile more similar to patients with well-
controlled LDL-c levels. 
 
The latest European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) consensus 
statement, as well as Swiss health authorities restrict the use of PCSK9i exclusively to patients with high 
LDL-c levels above 2.6 or 3.5 mmol/l.(11) This is in discordance to current evidence from randomized 
controlled trials that included patients with coronary heart disease and LDL-c equal or above 1.8 mmol/l, 
and that did not show an effect modification of PCSK9i cardiovascular benefit according to LDL-c levels. 
Eligibility criteria for use of PCSK9i in clinical practice has been already extended to all high-risk patients 
with cardiovascular disease and LDL-c equal or above 1.8 mmol/l despite maximal use of other lipid-
lowering drugs.(6) In our study, we found that those patients who would be newly eligible for PCSK9i have 
a good medical adherence to drugs and medical visits, better than those who meet current criteria for 
PSCK9i reimbursement and prescription. Cost-effectiveness analyses of PCSK9i showed that their price 
needs to be reduced to meet conventional cost-effectiveness thresholds.(17-19) However, these analyses 
are based on clinical trials that do not always reflect the real world effectiveness of PCSK9i in patients 
with cardiovascular disease. The safety profile of PSCK9i regarding medium-term adverse effects has 
been examined and these drugs are generally well tolerated, with limited impact on muscle symptoms,(1-3, 
20, 21) without differences between alirocumab and evolocumab.(22) However, long-term adverse effects are 
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unknown. Genetic PCSK9 deficiency is associated with higher risk of type 2 diabetes mellitus.(23-25) 
However, PCSK9i drugs may not increase the risk of diabetes, because they target mainly circulating 
PCSK9 with limited impact on pancreatic cells.(26) Our results suggest that extending the current eligibility 
for PCSK9i prescription would also mean treating more patients with high cardiovascular risk who would 
benefit from further lowering of LDL-c levels, although we acknowledge that the absolute benefit would be 
less significant than for very high-risk patients.  
 
Previous studies have mainly modelled the eligibility for prescribing a PCSK9i treatment in patients with 
coronary heart disease according to guidelines. However, few previous studies have reported 
characteristics of patients eligible with PCSK9i outside of randomized controlled trials. Previous modelling 
studies reported a low proportion of patients that would be eligible for PCSK9i, even after simulation of an 
oral lipid lowering therapy intensification and assuming full adherence.(27, 28) In a previous report, we 
compared the eligibility for PCSK9i according to the 2016 American College of Cardiology (ACC) and the 
2017 European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) consensus 
statements, and found that more patients would be eligible for PCSK9i using ACC criteria.(14) Saborowski 
and al. studied 38 patients treated with PCSK9i using eligibility criteria based on their cardiovascular risk 
and failure of other available lipid-lowering therapy.(29, 30) Zafrir and al. studied 133 patients from a 
regional lipid clinic, who had submitted an approval for PCSK9i use.(30) 
 
To our knowledge our analysis is among the first ones to report the control of cardiovascular risk factors 
and health behaviors of patients according to an extension of eligibility criteria for PCSK9i. We aimed 
especially to describe patients with elevated LDL-c levels, but who did not reach the current guideline 
criteria for PSCK9i prescription, in order to inform the societal impact of broadening current 
reimbursement criteria. 
 
Our study has limitations. First, the eligibility for PSCK9i was simulated and not observed, and we cannot 
exclude misclassification. For example, we were not able to assess the reasons for persistent high LDL-c 
levels one year after ACS. Particularly, we had no information on statin-associated muscle symptoms, 
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which could be an explanation for the relatively low proportion of patients using high-intensity statins and 
the uncontrolled LDL-c levels one year after the index ACS. Thus, the proportion of patients newly or 
currently eligible for PCSK9 may have been overestimated. However, this misclassification would not 
differ alter the control of main cardiovascular risk factors and health behaviors in these two groups. 
Second, our study compares patients at one point of time one year after an ACS, which make it a cross-
sectional study.  
 
In conclusion, more than half of patients with ACS would be additionally eligible for PCSK9i if 
reimbursement is extended from current guidelines to all patients with LDL-c equal or above 1.8 mmol/l. 
Patients with ACS additionally eligible for PCSK9i had lower cardiovascular risks factors and healthier 
lifestyle than those currently eligible. Expanding the eligibility for PCSK9i based on LDL-c levels may 
therefore increase the prescription to patients at lower cardiovascular risk.  
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Table 1.  Characteristics of patients one year after an acute coronary syndrome, according to eligibility 
for PCSK9i (n=3,025). 
 Not eligiblea 
Currently 
eligibleb 
Newly eligiblec 
p-value 
Not eligible 
vs 
Currently eligible 
p-value  
Not eligible   
vs 
Newly eligible 
Number of patients 1,071 (35.4) 415 (13.7) 1,539 (50.9)   
Demographics      
Age, years 64 (12) 64 (12) 62 (12) 0.47 0.001 
Female 180 (16.8) 81 (19.5) 314 (20.4) 0.22 0.02 
High educationd 
(n=2,856) 
361 (35.7) 114 (29.2) 485 (33.4) 0.020 0.23 
Comorbidities      
Familial 
hypercholesterolemiae 
142 (13.3) 93 (22.4) 358 (23.4) <0.001 <0.001 
Diabetes mellitusf 251 (23.4) 65 (15.6) 230 (14.9) 0.001 <0.001 
At risk alcohol 
consumptiong (n=2,626) 
107 (11.2) 48 (13.5) 168 (12.8) 0.26 0.26 
Depression (n=1,661)h 149 (26.7) 64 (25.6) 206 (24.2) 0.74 0.28 
Objective measures      
Total cholesterol, mmol/l 3.2 (0.5) 5.7 (1.0) 4.2 (0.6) <0.001 <0.001 
LDL-cholesterol, mmol/l 1.4 (0.3) 3.7 (0.9) 2.4 (0.4) <0.001 <0.001 
HDL-cholesterol, mmol/l  1.2 (0.4) 1.2 (0.3) 1.3 (0.3) 0.93 0.05 
Triglycerides, mmol/l 1.3 (0.8) 1.6 (0.7) 1.3 (0.7) <0.001 0.03 
Lipid-lowering therapy       
Statins (n=3,016) 1,059 (99.1) 304 (74.3) 1,465 (95.3) <0.001 <0.001 
High-Intensity statins 
(n=3,016) 
627 (58.7) 132 (32.3) 844 (54.9) <0.001 0.06 
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Data are given as number (percentage) or mean (standard deviation). 
aDefined as low-density lipoprotein cholesterol (LDL-c) <1.8 mmol/l.  
bDefined as LDL-c >3.5 mmol/l, or >2.6 mmol/l for patients who had several cardiovascular events. 
cDefined as LDL-c between 1.8 and 2.6 mmol/l, or between 2.6 and 3.5 mmol/l for patients with only one 
cardiovascular event. 
dDefined as a high school or university graduation or higher. 
eDefined as possible or probable familial hypercholesterolemia according to Dutch Lipid Clinic Network 
score. 
fDefined as having diabetes at the time of acute coronary syndrome (self-reported or use of antidiabetic 
medication or a hemoglobinA1c ≥ 6.5% at admission) or as the use of antidiabetic medication or a 
hemoglobinA1c ≥ 6.5% at one year. 
gDefined as more than 14 unit per week. 
hDefined as a score ≥ 16 in the Center for Epidemiological Studies-Depression (CES-D) self-assed 
questionnaire. 
iDefined as coronary heart disease, ischemic cerebrovascular disease, peripheral artery disease or 
unplanned revascularization, including the index ACS. 
Ezetimibe (n=3,025) 78 (7.3) 31 (7.5) 96 (6.2) 0.90 0.29 
Number of cardiovascular 
eventsi (n=3,023) 
   <0.001 <0.001 
One 790 (73.8) 153 (36.9) 1,253 (81.5)   
Two 256 (23.9) 235 (56.6) 261 (17.0)   
Three 24 (2.2) 27 (6.5) 24 (1.6)   
Quality of life      
EQ-5D-3L questionnairej 
score (n=2,371) 
6.2 (1.4) 6.5 (1.4) 6.2 (1.4) 0.001 0.77 
EQ visual analogue scalek 
score (n=2,387) 
76.5 (17.2) 73.2 (17.9) 77.8 (16.3) 0.004 0.08 
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jBased on EQ-5D-3L questionnaire, score from 5 (best quality of life) to 15 (worst quality of life). 
kBased on EQ visual analogue scale (EQ VAS), score from 0 (worst imaginable health state) to 100 (best 
imaginable health state).
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Data are given as number (percentage) or mean (standard deviation). 
aDefined as low-density lipoprotein cholesterol (LDL-c) <1.8 mmol/l. 
Table 2. Healthcare and preventive drug utilization one year after an acute coronary syndrome, 
according to eligibility for PCSK9i (n=3,025). 
 Not eligiblea 
Currently 
eligibleb 
Newly 
eligiblec 
p-value 
Not eligible 
vs  
Currently eligible 
p-value 
Not eligible 
vs 
Newly eligible 
Number of patients 1,071 (35.4) 415 (13.7) 1,539 (50.9)   
Health care utilization 
over one year 
     
At least one medical 
visit (n=2,739) 
975 (98.5) 
 
359 (97.6) 
 
1,370 (99.2) 
 
0.25 0.1 
At least one primary 
care visit (n=2,686) 
894 (92.4) 324 (91) 1,274 (93.5) 0.42 0.27 
At least one 
cardiologist visit 
(n=2,678) 
807 (83.5) 268 (75.1) 1,139 (84.1) 0.001 0.67 
Antiplatelet therapy 
(n=3,017)d 
1,045 (97.7) 389 (95.1) 1,502 (97.7) 0.01 0.99 
Antihypertensive 
therapye (n=3,017) 
1,022 (95.5) 365 (89.2) 1,436 (93.4) <0.001 0.02 
Number of drugsf 
(n=1,617) 
 
 
 
0.62 0.06 
0-5 348 (53.9) 102 (58) 477 (60)   
6-8 279 (43.2) 69 (39.2) 296 (37.2)   
>8 19 (2.9) 5 (2.8) 22 (2.8)   
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bDefined as LDL-c >3.5 mmol/l, or >2.6 mmol/l for patients who had several cardiovascular events. 
cDefined as LDL-c between 1.8 and 2.6 mmol/l, or between 2.6 and 3.5 mmol/l for patients with only one 
cardiovascular event. 
dDefined as the use of Acetylsalicylic acid. 
eInclude use of angiotensin converting enzyme inhibitors, or angiotensin II receptor blockers, or beta-
blockers, or calcium-channel blockers, or diuretics. 
fAcetylsalicylic acid , Clopidogrel, Prasugrel, Ticagrelor, anticoagulants, statins, lipid-lowering therapy 
other than statins, angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta-
blockers, calcium-channel blockers, diuretics, nonsteroidal anti-inflammatory drugs, Amiodarone, Digoxin, 
antidepressants, Dipyridamole, other antiarrhythmic drugs, immunosuppressive therapy, antiretroviral 
therapy, hormonotherapy. 
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Table 3. Control of cardiovascular risk factors one year after an acute coronary syndrome, according 
to eligibility for PCSK9i (n=3,025). 
 
Not 
eligiblea 
Currently 
eligibleb 
Newly eligiblec 
p-value 
Not eligible 
vs 
Currently eligible 
p-value 
Not eligible 
vs 
Newly eligible 
Number of patients 
1,071 
(35.4) 
415 (13.7) 1,539 (50.9) 
  
Blood pressure 
(n=2,921) 
   
  
Systolic blood pressure, 
mmHg 
132 (18) 137 (20) 132 (18) <0.001 0.86 
Diastolic blood 
pressure, mmHg 
77 (15) 81 (12) 79 (10) <0.001 0.001 
High systolic blood 
pressured 
284 (27.6) 135 (33.6) 420 (28.2) 
0.02 0.73 
Diabetes      
Diabetic patients with 
glycated hemoglobin 
≥7.5% (n=396) 
51 (25.9) 15 (35.7) 38 (24.2) 
 
0.2 
 
0.72 
Smoking status 
(n=3,024) 
     
Current smokers 227 (21.2) 116 (28) 346 (22.5) 0.02 0.51 
Weight (n=2,883)      
Body mass index, 
kg/m2  
27.1 (4.4) 27.2 (4.6) 27.2 (4.4) 0.66 0.48 
Obesee 206 (20.4) 92 (23.2) 310 (21) 0.24 0.71 
Physical activity      
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Data are given as number (percentage) or mean (standard deviation). 
aDefined as low-density lipoprotein cholesterol (LDL-c) <1.8 mmol/l.  
bDefined as LDL-c >3.5 mmol/l, or >2.6 mmol/l for patients who had several cardiovascular events. 
cDefined as LDL-c between 1.8 and 2.6 mmol/l, or between 2.6 and 3.5 mmol/l for patients with only one 
cardiovascular event. 
dDefined as systolic blood pressure > 140 mmHg. 
eDefined as Body Mass Index (BMI) > 30 kg/m2. 
fDefined as ≤ 600 Metabolic Equivalent of Task (MET) minutes per week of physical activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sedentaryf 343 (32) 142 (34.2) 468 (30.4) 0.42 0.38 
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Figure 1. Change in health behaviors over the year after an acute coronary syndrome, according 
to eligibility for PCSK9i (n=3,025). 
aCurrent smokers with motivation to quit smoking ≥ 5 on motivation scale.  
bDefined as ≤ 600 Metabolic Equivalent Task (MET) minutes per week of physical activity.  
cDefined as the ratio of negative weight change over the weight at the index acute coronary syndrome 
(ACS). 
dDefined as Body Mass Index (BMI) > 30 kg/m2. 
